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In traumatic brain injury (TBI) the analysis of neuroinflammatory mechanisms gained increasing interest. In this context certain
immunocompetent cells might play an important role. Interestingly, in the actual literature there exist only a few studies focusing
on the role of monocytes and granulocytes in TBI patients. In this regard it has recently reported that the choroid plexus represents
an early, selective barrier for leukocytes after brain injury. Therefore the aim of this study was to evaluate the very early dynamics
of CD14+ monocytes and CD15+ granulocyte in CSF of patients following severe TBI with regard to the integrity of the BBB.
Cytometric flow analysis was performed to analyze the CD14+monocyte andCD15+ granulocyte population inCSF of TBI patients.
The ratio of CSF and serum albumin as a measure for the BBB’s integrity was assessed in parallel. CSF samples of patients receiving
lumbar puncture for elective surgery were obtained as controls. Overall 15 patients following severe TBI were enrolled. 10 patients
were examined as controls. In patients, the monocyte population as well as the granulocyte population was significantly increased
within 72 hours after TBI. The BBB’s integrity did not have a significant influence on the cell count in the CSF.
1. Introduction
Traumatic brain injury (TBI) is especially prevalent in young
adults [1] and represents one of the leading causes of death
and of persistent damage of neurocognitive functions. The
outcome is primarily determined by the initial trauma result-
ing from the physical impact and secondarily determined
by the extent of secondary injury to the brain in terms of
brain edema, increased intracranial pressure, and delayed cell
destruction [2]. These secondary injury mechanisms could
be responsible for the development of neurological deficits
after TBI evolving minutes to days or even months after
the primary mechanical injury [3]. The delayed incidence of
the secondary injury mechanisms indicates that there might
be a time window for therapeutic interventions to reduce
brain tissue damage and improve the functional neurolog-
ical outcome [3]. Therefore improved understanding of the
complex processes following TBI [3] is crucial for the devel-
opment of an effective neuroprotective treatment. Although
the key role of the systemic cellular immune response in
patients following multiple trauma has been emphasized by
several authors, there is only a limited number of studies
analyzing the cellular response of the key inflammatory cells
such as monocytes and granulocytes in the cerebrospinal
fluid (CSF) of patients following TBI [4–6]. Monocytes are
characterized by CD14, a 56 kDa cell membrane anchored
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protein [7, 8]. In parallel, the carbohydrate antigen CD15
(the carbohydrate antigen 3-fucosyl-N-acetyl-lactosamine)
with an approximate molecular mass of 165 and 105 kDa is
expressed on membrane glycoproteins of neutrophil granu-
locytes [9, 10]. Under physiologic conditions the CSF is sep-
arated from peripheral and cerebral blood flow by the blood
brain barrier (BBB). In analyzing the dynamics of monocytes
and granulocytes in CSF of patients after TBI, the question
arises whether potential changes of cellular contents occur
due to a disrupted BBB or by a certain mechanism still to be
explained. It is well known that the leukocyte count of the
CSF is far lower compared to peripheral blood. Therefore a
disruptedBBBpotentially leads to an increase of leukocytes in
the CSF following cell leakage due to disrupted blood vessels.
Therefore the aim of the present study was to evaluate
the fraction of CD14+ monocytes and CD15+ granulocytes
in CSF of patients following TBI beginning at the time of
admission until 72 hours (hrs) after TBI. The influence of the
BBB integrity on the number of monocytes and granulocytes
in CSF was also assessed in this context.
2. Patients and Methods
2.1. Study Design and Patient Collective. The study protocol
was approved by the university’s board of ethics (reference
number 330/03). Inclusion criteria for prospective enrolment
were presence of isolated closed TBI, initial Glasgow Coma
Score (GCS) ≤ 8 points (i.e., severe brain injury), proof of
intracranial bleeding (ICB) on the initial cranial computed
tomography scan (CCT; performed within 90 minutes after
TBI), and the indication for placing an external ventricular
drainage (EVD) catheter. Exclusion criteria were a history of
preexisting neurological,malignant, or chronic inflammatory
disease. Written informed consent was obtained when the
patient regained consciousness. In case of remaining uncon-
scious, a next of kin or a legal representative was asked for the
presumed consent.
2.2. Clinical and Surgical Procedures. An external ventricu-
lar drainage (EVD) catheter (TraumaCath, Integra Neuro-
sciences, Plainsboro, USA) was placed in the frontal horn
of the lateral ventricle using CT fluoroscopy guidance to
continuously monitor the intracranial pressure (ICP) and to
drain CSF [11]. After a CT scan performed to control the
correct placement of the drainage, the patients were referred
to the intensive care unit (ICU) and treated according to the
guidelines of the Brain Trauma Foundation [12]. If the ICP
remained under 15mmHg for at least 72 hrs withoutmannitol
administration or CSF drainage, the EVD was removed.
2.3. Sampling Procedures. The first sampling took place
immediately after the insertion of the EVD (90 ± 45 min-
utes after admission to the hospital). Further samples were
obtained 12, 24, 48, and 72 hrs after TBI. At every sampling
time point 4mL of drained CSF, 5mL of peripheral serum
blood, and 5mLof EDTAbloodwere collected. 500 𝜇L ofCSF
was sent to the institute of laboratory medicine of our uni-
versity hospital for the determination of the total cell counts
and albumin levels in CSF.The serum blood was used for the
determination of the albumin levels in peripheral blood by
the institute of laboratorymedicine. Albumin levels were nec-
essary for the evaluation of the blood brain barrier (BBB).The
EDTA blood was sent to the institute of laboratory medicine
and was used for peripheral differential blood counts.
2.4. Fluorescence Labeling. For the fluorescence activated
cell sorting (FACS) analysis, 3mL of the cerebrospinal fluid
samples was centrifuged with 1200G at 4∘C for 10 minutes
to remove the supernatant and processed immediately. The
cell pellet was resuspended in 200𝜇L FC buffer suspension
(0.01M phosphate buffered saline, pH 7.2, 1% bovine serum
albumin, and 5% fetal calf serum (FCS; 0.02% NaN
3
)).
20𝜇L of the resuspension was incubated for 20 min-
utes with 3 𝜇L fluorochrome-labeled antibodies in the dark
on ice. All antibodies CD14 TC and CD15 FITC (Caltag
Laboratories, Hamburg, Germany) were used in single-stain
arrays. For lysing of the erythrocytes, 500𝜇L FACS lysing
solution (Caltag Laboratories, Hamburg, Germany) was used
and afterwards the suspension was incubated for another 10
minutes. After washing with 500𝜇L PBS (5% fetal calf serum
(FCS; 0.02% NaN
3
, Pettenkofer, Munich, Germany)) twice,
the suspensionwas centrifuged again for 10minuteswith 1200
rounds per minute at 4∘C.
2.5. Flow Cytometric Analysis. The FACS analysis was per-
formed using a four-channel Epics XL MCL flow cytometer
(Beckman-Coulter, Krefeld, Germany) with an air-cooled
15mW 488 nm argon ion laser. A 530 nm filter for FITC
(fluorescein isothiocyanate) and a >650 nm filter for TC
(Tri-Color, Caltag Laboratories, Hamburg, Germany) were
applied. Data acquisition was obtained using the Expo 32
Software (Beckman-Coulter, Krefeld, Germany). Spectral
compensations and instrument settings were appropriately
adjusted. Fluidics and Instruments were regularly checked
using FlowCheck beads (Beckman-Coulter, Krefeld, Ger-
many). For a respective analysis, the cytometer counted 5000
events (cells) in a list mode. The free WinMDI Software
(Version 2.8, Bio-Soft Net [13]) was used for data analysis.
Antibody-positive cells were determined as the most positive
on side scatter versus TC (CD14) and FITC (CD15) positive
cells, respectively. Antibody-positive cells were counted as
percentage of the total cell count.
2.6. Assessment of the Blood Brain Barrier Function. In
order to determine whether CD14+ monocytes’ and CD15+
granulocytes’ dynamics correlate to posttraumatic BBB dis-
ruption, the ratio of CSF and serum albumin (𝑄alb) was
calculated at each sampling time point. Albumin levels were
evaluated by using standardized turbidimetric assays (Cobas
Integra Albumin, Roche Diagnostics, Mannheim, Germany).
According to Reiber and Felgenhauer, 𝑄alb is a sensitive
parameter for the analysis of the BBB [14]. In this study, the
disturbance of the BBB was assessed as follows: 𝑄alb values
below 0.007were considered as normal, values between 0.007
and 0.01 as mild dysfunction, values between 0.01 and 0.02
as moderate, and levels above 0.02 as severe dysfunction
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of the BBB. Normal and mild dysfunction were defined as
intact BBB whereas moderate and severe dysfunction were
defined as disrupted BBB. To assess the influence of the BBB’s
function on the dynamics of the monocytes, the enrolled
patients were divided into two groups: group I presenting
with an intact BBB and group II with a defect BBB.
2.7. DataAnalysis. Data are given inmean± standard error of
the mean (SEM). For comparing patient values with control
values or the patient value at the time of admission, the
data was analyzed using ANOVA (analysis of variance on
ranks) for nonparametric data according to Kruskal-Wallis.
For analysis of significant differences over the course of time
ANOVA was performed using the Student-Newman-Keuls
test. For determination of specific differences Dunn’s test was
performed. The level of significance was set to ≤0.05. For all
statistical analysis the Sigma Stat 3.0 software package (SPSS
Inc., Chicago, USA) was used.
3. Results
3.1. Patients and Demographic Data. In total, 23 patients with
isolated severe TBI were enrolled (8 females and 15 males;
age 46 ± 5 years). Eight patients died within 24 hrs after TBI,
because of therapy resistant brain swelling and/or brain stem
herniation and thus had to be excluded. CSF was obtained
from 10 control patients (5 females and 5 males; age 44 ±
9 years) who underwent spinal anesthesia for an elective
orthopedic procedure of the lower extremity.
3.2. Dynamics of CD14+ Monocytes. The baseline value of
the control group monocyte population was 2.6 ± 0.6%.
At admission the monocyte count was 2.32 ± 0.6% in the
TBI patient group, not significantly different to the control
group. The monocyte population increased to 4.10 ± 1.0% at
12 hrs, to 4.61 ± 1.4 % at 24 hrs, and to 5.26 ± 1.0% at 48 hrs.
Although a continuous increase was observed, there was
no statistically significant difference in comparison to the
admission level. In addition, the monocyte populations at 12,
24, and 48 hrs were not significantly different in comparison
to the baseline level of healthy controls. However, 72 hrs after
TBI the monocyte population accounted for 6.48 ± 0.8% and
was thereby significantly higher in comparison to the value
at admission. Furthermore the monocyte population was
significantly higher in comparison to the baseline level of the
healthy control group (see Figure 1).
3.2.1. Group I (Intact BBB, 𝑛 = 9). At admission the CD14+
monocyte count of patients with intact BBB was 2.61 ± 0.9%,
which was not significantly different in comparison to the
baseline level of the control group. The fraction increased
to 4 ± 1.5% and 4.34 ± 1.4% at 12 hrs and 24 hrs after
TBI, respectively. The cell counts were still not significantly
different in comparison to the cell level at admission. In
addition, there was no significant difference in comparison
to the baseline level of the control group. At 48 hrs after
TBI the population accounted for 6.40 ± 1.5%, which was
significantly higher than the baseline level of the control
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Figure 1: Dynamics of CD14+ monocytes. The graph demonstrates
the number ofCD14+monocytes in percent (%) of all CSF cells at the
different sampling time points. Data are given in mean ± standard
error of the mean. ∗𝑝 < 0.05 versus control group; #𝑝 < 0.05 versus
admission.
group (𝑝 < 0.05). At 72 hrs the CD14+ monocytes further
increased to a value of 6.91 ± 1.0%. This was significantly
higher than the baseline value of the control group and
significantly elevated compared to the admission value.
3.2.2. Group II (Disrupted BBB, 𝑛 = 6). At the time of
admission the monocyte population accounted for 1.89 ± 0.9
and it was only slightly but not significantly higher at 12 hrs
after TBI (4.25 ± 1.6%). At 24 hrs the population dropped
to a level of 3.53 ± 1.1% and there was still no significance
compared to the value at the time of admission (0 hrs). In
addition, the monocyte population at the time of admission,
12 hrs, and 24 hrs after TBI was not significantly different
in comparison to the baseline level of the control group. At
48 hrs and at 72 hrs after TBI the populationswere 5.02± 3.2%
and 5.83 ± 1.4%, respectively; both values were significantly
higher than the value at the time of admission as well as the
baseline level of the control group.
3.2.3. BBB Evaluation. Regarding the evaluation of the BBB
there were no significant differences between group I with
intact BBB and group II with disrupted BBB at the defined
sample points (0, 12, 24, 48, and 72 hrs after TBI; see Figure 2).
3.3. Dynamics of CD15+ Granulocytes. The control group
value accounted for 0.98± 0.2%.Thepopulation of theCD15+
granulocytes was already significantly elevated at admission
(9.15 ± 1.6%) compared to the baseline level of controls. At
12 hrs the value increased to 24.65 ± 1.6% and was therefore
significantly higher in comparison to the admission time
point. The granulocyte populations were 25.9 ± 3.1, 34.3 ±
5.0, and 25.5 ± 3.5 at 24, 48, and 72 hrs, respectively, so that
the values remained significantly elevated compared to the
admission levels as well as the baseline level of controls (see
Figure 3).
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Figure 2: Dynamics of CD14+monocytes and function of the blood
brain barrier.The graph demonstrates the number of CD14+mono-
cytes in percent (%) of all CSF cells. Graphs in white demonstrate
data of patients with intact blood cerebrospinal fluid barrier (𝑛 = 9),
whereas graphs in grey demonstrate data of patients with disrupted
blood cerebrospinal fluid barrier (𝑛 = 6). Data are given in mean ±

















Figure 3: Dynamics of CD15+ granulocytes. The graph demon-
strates the number of CD15+ granulocytes in percent (%) of all CSF
cells at the different sampling points. Data are given in mean ±
standard error of themean. ∗𝑝 < 0.05 versus control group; #𝑝 < 0.05
versus admission.
3.3.1. Group I (Intact BBB, 𝑛 = 9). The population of gran-
ulocytes was already significantly elevated (8.61 ± 1.3%) at
admission compared to the baseline level of the control group
(0.98± 0.2%).At 12 hrs afterTBI the population accounted for
26.96± 2.6%,whichwas significantly higher in comparison to
admission.The granulocytes were 25.42 ± 4.6%, 33.38 ± 7.0%,
and 22.27 ± 4.6% at 24 hrs, 48 hrs, and 72 hrs, respectively.
These populations remained significantly higher in compar-
ison to admission. In addition the granulocytes in group I
were significantly higher compared to the baseline level of the


















Figure 4: Dynamics of CD15+ granulocytes and function of the
blood brain barrier. The graph demonstrates the number of CD15+
granulocytes in percent (%) of all CSF cells. Graphs in white
demonstrate data of patients with intact blood cerebrospinal fluid
barrier (𝑛 = 9), whereas graphs in grey demonstrate data of patients
with disrupted blood cerebrospinal fluid barrier (𝑛 = 6). Data are
given inmean± standard error of themean. ∗𝑝 < 0.05 versus control
group; #𝑝 < 0.05 versus admission.
3.3.2. Group II (Disrupted BBB, 𝑛 = 6). The population
of granulocytes accounted for 14.92 ± 1.0% at admission
and was therefore significantly higher in comparison to the
control group (0.98 ± 0.2%). At 12 hrs and at 48 hrs the values
increased to 24.48 ± 1.3% and 28.37 ± 2.9%, respectively.
At 48 hrs granulocytes increased to 35.80 ± 7.6% and were
therefore significantly higher in comparison to admission.
At 72 hrs granulocytes dropped to 22.27 ± 4.6%, so that
there was no further significant difference in comparison to
admission levels.The populations of granulocytes in group II
were significantly higher in comparison to the baseline level
of the control group for every sampling time point.
3.3.3. BBB Evaluation. Regarding the evaluation of the BBB
there was no significant difference between group I with
intact BBB and group II with disrupted BBB (see Figure 4).
3.4. CSF Total Cell Count. Theabsolute level of cells (total cell
count) as well as the percentages of monocytes and granulo-
cytes at the various sample points is given in Tables 1, 2, and 3.
Therewas no significant difference found comparing the sam-
pling points to base line levels at admission.There was also no
difference comparing patients with intact and disrupted BBB.
3.5. Peripheral Blood Monocyte and Granulocyte Count. The
populations of monocytes and granulocytes in peripheral
blood are provided in Table 4. There were no significant
changes over the course of time.
4. Discussion
In the present study the dynamics of CD14+ monocytes and
CD15+ granulocytes in the cerebrospinal fluid of patients
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Table 1: Total cell count in the CSF of patients.
Cells/𝜇L Admission 12 hrs 24 hrs 48 hrs 72 hrs
All patients (𝑛 = 15) 30.7 ± 5.6 17.8 ± 2.5 16.9 ± 3.0 24.6 ± 4.2 27.8 ± 4.9
Intact BBB (𝑛 = 9) 31.4 ± 7.8 12.75 ± 1.8 11.0 ± 1.2 17.5 ± 2.3 25.4 ± 5.9
Disrupted BBB (𝑛 = 6) 29.8 ± 8.7 24.5 ± 4.1 24.7 ± 5.9 34.2 ± 8.5 31.0 ± 9.0
Total numbers of CSF cells. Data given as mean ± SEM.
BCSFB: blood cerebrospinal fluid barrier.
CSF: cerebrospinal fluid.
TBI: traumatic brain injury.
Table 2: Monocyte count in the CSF of patients.
Monocyte count (%) Admission 12 hrs 24 hrs 48 hrs 72 hrs
All patients (𝑛 = 15) 5.3 ± 0.4 6.9 ± 0.6 6.3 ± 0.4 7.6 ± 0.9 5.7 ± 0.5
Intact BBB (𝑛 = 9) 5.6 ± 0.6 6.7 ± 0.7 6.1 ± 0.5 7.4 ± 0.7 5.9 ± 0.76
Disrupted BBB (𝑛 = 6) 4.9 ± 0.4 7.4 ± 0.9 6.6 ± 0.6 7.8 ± 1.8 5.2 ± 0.7
Percentages of monocytes. Data given as mean ± SEM.
BCSFB: blood cerebrospinal fluid barrier.
CSF: cerebrospinal fluid.
TBI: traumatic brain injury.
Table 3: Granulocyte count in the CSF of patients.
Granulocyte count [%] Admission 12 hrs 24 hrs 48 hrs 72 hrs
All patients (𝑛 = 15) 63.9 ± 3.7 69.9 ± 3.2 70.6 ± 3.4 66.2 ± 5.5 65.9 ± 3.6
Intact BBB (𝑛 = 9) 63.9 ± 4.1 71.4 ± 2.8 71.9 ± 3.2 64.7 ± 8.4 64.4 ± 4.3
Disrupted BBB (𝑛 = 6) 64 ± 6.0 67.7 ± 6.1 68.5 ± 6.4 68.5 ± 5.1 68 ± 5.2
Percentages of granulocytes. Data given as mean ± SEM.
BCSFB: blood cerebrospinal fluid barrier.
CSF: cerebrospinal fluid.
TBI: traumatic brain injury.
Table 4: Peripheral blood monocytes and granulocytes.
Cells [%] Admission 12 hrs 24 hrs 48 hrs 72 hrs
Monocytes (𝑛 = 15) 5.3 ± 0.4 7.0 ± 0.6 6.3 ± 0.4 7.6 ± 1.0 5.7 ± 0.5
Intact BBB (𝑛 = 9) 5.6 ± 0.6 6.7 ± 0.8 6.1 ± 0.6 7.4 ± 0.8 6.0 ± 0.7
Disrupted BBB (𝑛 = 6) 4.9 ± 0.5 7.4 ± 1.1 6.6 ± 0.7 7.8 ± 2.2 5.2 ± 0.8
Granulocytes (𝑛 = 15) 64.0 ± 3.7 69.9 ± 3.2 70.6 ± 3.4 70.9 ± 2.9 65.9 ± 3.6
Intact BBB (𝑛 = 9) 64.0 ± 4.8 71.4 ± 3.2 71.9 ± 3.6 72.5 ± 3.4 64.4 ± 4.9
Disrupted BBB (𝑛 = 6) 64.0 ± 6.6 67.7 ± 6.7 68.5 ± 7.0 68.5 ± 5.5 68 ± 5.7
Percentages of cells. Data given as mean ± SEM.
BCSFB: blood cerebrospinal fluid barrier.
TBI: traumatic brain injury.
suffering from traumatic brain injury were evaluated in the
direct posttraumatic course over 72 hours for the first time.
CD14+ monocyte and CD15+ granulocyte cell populations
were significantly elevated within the first 72 hrs after TBI
compared to baseline levels at admission to hospitals as well
as in comparison to healthy controls. Regarding a potential
dysfunction of the BBB no significant difference was found
between TBI patients with intact BBB and TBI patients with
disrupted BBB, respectively.
Only patients with isolated TBI were included to avoid
an increase of monocytes and granulocytes in the peripheral
blood not resulting from TBI and a potential consecutive
bias. In addition the inclusion criteria in terms of severe
TBI (GCS ≤ 8) and signs of intracerebral hemorrhage were
established to ensure that an adequate trauma to the brain
had happened possibly resulting in detectable and significant
changes of the CSF on cellular level. In conclusion the
inclusion criteria lead to enrollment of patients in critical
conditions, so that research as conducted in this study should
form the basis of future research regarding especially a
potential modification of therapeutic options after TBI to
avoid secondary brain damage.
In general the effect of moderate (and even mild) TBI
on the dynamics of monocytes and granulocytes would be
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additionally interesting for the understanding of TBI and the
processes happening in the brain on cellular level. However
harvest of CSF is quite difficult to account for in patients
who are not considered to get an EVD placed. In the current
literature several studies report detection of pro- and anti-
inflammatory mediators such as cytokines or interleukins in
the CSF of patients [15]. However, there is also evidence in
the literature that secondary brain damage may also develop
without an increase of interleukins in CSF [16]. In this context
a functional involvement of immunocompetent cells like
monocytes [17–21] and granulocytes [22, 23] in the formation
of secondary brain damage was described.
In the present study the population of CD14+ monocytes
and CD15+ granulocytes increased significantly within the
first 72 hrs after TBI compared to the corresponding popu-
lations of the control group and even to the cell populations
at the time of admission. Consecutively the question arose
whether this was due to a nonmodulated influx of these cells
from the peripheral blood into CSF because of a disrupted
BBB or whether the cells were transported across the BBB
via certain mechanisms to be described. In this context the
presented results demonstrate that the integrity of the BBB
had no significant influence on the populations of the CD14+
monocytes and CD15+ granulocytes in the time course of the
first 72 hours after TBI. In addition there was no significant
drop of monocyte or granulocyte populations detected in the
peripheral blood. Therefore our data does not support the
theory of a nonmodulated influx of cells from the peripheral
blood. However, subdividing into groups with a rather small
number of 𝑛 < 10 has to be critically interpreted from the
statistical point of view. In this context recent publications
demonstrated a monocyte trafficking across the BBB using a
transmission electronmicroscopy in a rat TBImodel [24, 25].
In this regard Schwartz and Baruch recently reported that the
choroid plexus represents an early entry site for leukocytes
after injury of the CNS (Central Nervous System) [26].
Shechter et al. also recently found that monocytes primarily
traffic through the choroid plexus after CNS injury [27].
These recently reported findings possibly help to explain the
significantly elevated populations of CD14+ monocytes and
CD15+ granulocytes in the CSF in the early phase of TBI
patients in the present study.
The CD15+ granulocytes were already significantly and
nearly tenfold increased at the time of admission indicating a
very fast response of the quantity of granulocytes after TBI. In
addition the granulocyte population further increased; 12 hrs
after TBI the population was already significantly higher
than at the time of admission. These data show that the
granulocytes are fast-responder and available for migration
into the CSF in sufficient numbers. Also the data about
the dynamics of the cells provide initial evidence that the
granulocytes could play an important role in the very early
posttraumatic phase after severe TBI.
The increase of CD14+ monocytes did not lead to a
significantly higher level of the monocyte population until
72 hrs after TBI. The comparably slower increase of mono-
cytes could mean that these cells are not as much involved
in the early response after TBI as granulocytes. This could
however just indicate that monocytes are far more immobile
than granulocytes or just not in an equal number available for
migration into the CSF. In this regard it would be very inter-
esting to determine the population of activated cells among
the overall CD14+ monocytes. Future work is therefore
necessary to further understand the role ofmonocytes in TBI.
A limitation of this study to be mentioned is that only
dynamics of CD14+ monocytes and CD15+ granulocytes
were analyzed and that the distinct cause of the resulting
increase was not determined. In this regard it has to be stated
that the placement of an EVD itself can be considered as some
kind of brain injury. Hence, the inflammatory response in the
CSF could potentially be caused by placement of the EVD.
This is a potential bias, which is not excluded by the control
CSF group. In the control groupCSFwas obtained via lumbar
puncture for spinal anesthesia which is a completely different
injury model concerning the CSF collection. However our
study was initiated to measure the effect of immunocom-
petent cells in TBI in the early posttraumatic phase. Strictly
speaking this study compared the inflammation response
after two known TBI events (the first event(s) up to 90 min-
utes previous to the second TBI event considering placement
of the EVD as TBI event) to a control group with a minor
spinal injury in terms of spinal anesthesia.This should be kept
in mind when interpreting the results. Therefore a further
limitation of the study is that a second control group with
patients needing EVDor a ventricular shunt for other reasons
than TBI (e.g., hydrocephalus) could have also been included
possibly allowing for recognition of potential effects caused
by placing an EVD. We were not able to provide data from
such appropriate control patients in our academic university
trauma department. Therefore a multicenter study should
be considered for future investigation. However this study
analyzed the dynamics of monocytes and granulocytes after
severe TBI events which was an important first step that
future research can build on.
In conclusion the populations of CD14+ monocytes and
CD15+ granulocytes significantly increased compared to the
cell populations of the control group and even to the cell
populations at the time of admission in the patient group, but
it remained unclear how this increase occurred and whether
the increase influenced the outcome of TBI patients. Further
research is necessary and is the focus of our study group’s
current work.
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[8] K. Borzęcka, A. Płóciennikowska, H. Björkelund, A. Sobota,
and K. Kwiatkowska, “CD14 mediates binding of high doses
of LPS but is dispensable for TNF-𝛼 production,” Mediators of
Inflammation, vol. 2013, Article ID 824919, 12 pages, 2013.
[9] S. Zahler, C. Kowalski, A. Brosig, C. Kupatt, B. F. Becker,
and E. Gerlach, “The function of neutrophils isolated by a
magnetic antibody cell separation technique is not altered
in comparison to a density gradient centrifugation method,”
Journal of Immunological Methods, vol. 200, no. 1-2, pp. 173–179,
1997.
[10] S. C. Stocks, M. Albrechtsen, andM. A. Kerr, “Expression of the
CD15 differentiation antigen (3-fucosyl-N-acetyl-lactosamine,
LeX) on putative neutrophil adhesionmolecules CR3 andNCA-
160,” Biochemical Journal, vol. 268, pp. 275–280, 1990.
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